Krebs Biochemicals & Industries Ltd

Krebs Biochem Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Krebs Biochemicals & Industries Ltd

₹ 107 -1.31%
13 Dec - close price
krebsbiochem.com BSE: 524518 NSE: KREBSBIO
About

Incorporated in 1991, Krebs Biochemicals & Industries Ltd is presently engaged in manufacturing of active pharmaceutical ingredients.

Key Points

Product Portfolio
a) Androstenedione which is used as Steroid Intermediate
b) Lovastatin used as Anti-cholesterol medication
c) Simvastatin is also used as Anti-cholesterol medication
d) Upcoming Products: Amlodipine, Cetirizine, Orlistat, Telmisartan, Serratiopepetidase and Phenylephrine. [1]

Website BSE NSE - BE
  • Market Cap ₹ 230 Cr.
  • Current Price ₹ 107
  • High / Low ₹ 129 / 60.0
  • Stock P/E
  • Book Value ₹ -60.4
  • Dividend Yield 0.00 %
  • ROCE -19.0 %
  • ROE %
  • Face Value ₹ 10.0
Edit ratios

Pros

Cons

  • Company has low interest coverage ratio.
  • The company has delivered a poor sales growth of 1.09% over past five years.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs

Edit Columns
Loading peers table ...

Quarterly Results

Figures in Rs. Crores

Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024
11.98 21.81 19.16 10.64 20.94 9.09 11.46 10.58 14.89 12.98 11.97 12.89 12.86
19.76 31.71 28.94 16.91 22.84 12.07 16.08 13.20 15.79 15.07 15.09 15.08 15.58
Operating Profit -7.78 -9.90 -9.78 -6.27 -1.90 -2.98 -4.62 -2.62 -0.90 -2.09 -3.12 -2.19 -2.72
OPM % -64.94% -45.39% -51.04% -58.93% -9.07% -32.78% -40.31% -24.76% -6.04% -16.10% -26.07% -16.99% -21.15%
0.13 0.20 0.79 0.13 0.27 0.02 0.19 0.04 0.17 0.03 0.21 0.03 0.09
Interest 1.78 1.82 0.28 0.30 0.74 0.90 1.03 1.10 1.13 1.19 1.27 1.32 1.42
Depreciation 1.42 1.42 2.05 1.69 1.69 1.69 1.48 1.65 1.71 1.73 1.67 1.69 1.71
Profit before tax -10.85 -12.94 -11.32 -8.13 -4.06 -5.55 -6.94 -5.33 -3.57 -4.98 -5.85 -5.17 -5.76
Tax % 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
-10.85 -12.94 -11.31 -8.14 -4.06 -5.55 -6.94 -5.33 -3.57 -4.98 -5.85 -5.17 -5.76
EPS in Rs -5.03 -6.00 -5.25 -3.78 -1.88 -2.57 -3.22 -2.47 -1.66 -2.31 -2.71 -2.40 -2.67
Raw PDF

Profit & Loss

Figures in Rs. Crores

Jun 2013 15m Sep 2014 15m Mar 2015 6m Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 TTM
11 0 0 1 3 34 48 33 54 60 52 50 51
24 4 5 14 11 41 58 52 71 94 68 59 61
Operating Profit -13 -4 -5 -12 -8 -8 -10 -19 -18 -34 -16 -9 -10
OPM % -117% -1,088% -248% -22% -20% -56% -33% -57% -30% -17% -20%
6 0 3 1 -0 -1 0 0 1 1 1 0 0
Interest 1 0 4 1 3 5 6 6 6 5 3 5 5
Depreciation 8 0 2 4 4 4 4 5 5 6 7 7 7
Profit before tax -16 -4 -8 -16 -16 -18 -20 -29 -28 -45 -25 -20 -22
Tax % -5% 10% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0%
-15 -4 -8 -16 -16 -18 -20 -29 -28 -45 -25 -20 -22
EPS in Rs -13.22 -3.78 -6.82 -10.33 -9.67 -10.73 -12.03 -16.04 -14.45 -20.65 -11.45 -9.15 -10.09
Dividend Payout % 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0%
Compounded Sales Growth
10 Years: 16%
5 Years: 1%
3 Years: -2%
TTM: 10%
Compounded Profit Growth
10 Years: -3%
5 Years: 0%
3 Years: 9%
TTM: -2%
Stock Price CAGR
10 Years: 12%
5 Years: 4%
3 Years: -14%
1 Year: 33%
Return on Equity
10 Years: %
5 Years: %
3 Years: %
Last Year: %

Balance Sheet

Figures in Rs. Crores

Jun 2013 Sep 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Sep 2024
Equity Capital 10 10 10 13 14 14 17 18 20 22 22 22 22
Reserves -2 -6 9 -0 -12 -32 -31 -43 -62 -97 -121 -141 -152
93 93 61 31 48 56 53 66 111 143 183 194 205
37 41 29 73 73 87 103 93 91 122 91 104 111
Total Liabilities 138 138 108 116 122 126 142 134 159 190 175 178 185
51 58 58 93 102 101 101 105 118 139 147 150 149
CWIP 7 0 0 11 4 4 3 4 12 8 4 2 1
Investments 0 0 0 0 0 0 0 0 0 0 0 0 0
80 80 50 13 16 21 38 24 29 43 24 26 36
Total Assets 138 138 108 116 122 126 142 134 159 190 175 178 185

Cash Flows

Figures in Rs. Crores

Jun 2013 Sep 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
-2 49 -45 -15 -11 -6 4 -36 -15 -17 -25 2
6 0 -3 -4 -5 -3 -4 -10 -23 -23 -13 -8
-4 -49 54 13 16 9 17 29 38 40 37 6
Net Cash Flow -0 0 6 -6 -0 0 17 -17 1 -1 -0 0

Ratios

Figures in Rs. Crores

Jun 2013 Sep 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Debtor Days 30 10 180 3 22 2 2 5 4 14
Inventory Days 2,368 14,704 2,162 337 142 345 234 230 170 543
Days Payable 1,517 32,250 4,360 510 339 521 292 340 217 1,051
Cash Conversion Cycle 881 -17,536 -2,018 -170 -175 -174 -57 -106 -44 -494
Working Capital Days -446 -6,532 -2,132 -275 -315 -267 -119 -200 -162 -250
ROCE % -15% -4% -8% -26% -26% -26% -36% -57% -40% -57% -29% -19%

Shareholding Pattern

Numbers in percentages

1 Recently
Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024
72.74% 72.74% 72.74% 72.74% 72.72% 72.74% 72.74% 72.74% 72.74% 72.74% 72.74% 72.74%
0.01% 0.01% 0.01% 0.01% 0.33% 0.50% 0.50% 0.50% 0.50% 0.50% 0.50% 0.50%
27.25% 27.25% 27.25% 27.26% 26.95% 26.76% 26.77% 26.76% 26.77% 26.75% 26.75% 26.76%
No. of Shareholders 8,1669,5319,5339,6509,2949,3159,3939,0308,9908,9098,8489,425

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Right Issue